635 related articles for article (PubMed ID: 32979839)
41. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.
Dorta-Suárez M; de Miguel M; Amor-Carro O; Calderón JM; González-Ortega M; Rodríguez-Abreu D
Cancer Treat Rev; 2024 Mar; 124():102671. PubMed ID: 38281403
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
[TBL] [Abstract][Full Text] [Related]
43. Amivantamab for the treatment of
Vyse S; Huang PH
Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
[TBL] [Abstract][Full Text] [Related]
44. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
45. [Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Pi C; Zhang YC; Xu CR; Zhou Q
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):94-97. PubMed ID: 28219202
[TBL] [Abstract][Full Text] [Related]
46. EGFR-mutant NSCLC: emerging novel drugs.
Ye L; Chen X; Zhou F
Curr Opin Oncol; 2021 Jan; 33(1):87-94. PubMed ID: 33122578
[TBL] [Abstract][Full Text] [Related]
47. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
48. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
49. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Piotrowska Z; Tan DS; Smit EF; Spira AI; Soo RA; Nguyen D; Lee VH; Yang JC; Velcheti V; Wrangle JM; Socinski MA; Koczywas M; Janik JE; Jones J; Yu HA
J Clin Oncol; 2023 Sep; 41(26):4218-4225. PubMed ID: 37384848
[TBL] [Abstract][Full Text] [Related]
50. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
Ma F; Shi X; Meng W; Zhang J; Zhao L; He X; Zhao J
Zhongguo Fei Ai Za Zhi; 2014 Jul; 17(7):575-80. PubMed ID: 25034590
[TBL] [Abstract][Full Text] [Related]
51. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
52. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
53. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
[TBL] [Abstract][Full Text] [Related]
55. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
Steuer CE; Khuri FR; Ramalingam SS
Cancer; 2015 Apr; 121(8):E1-6. PubMed ID: 25521095
[TBL] [Abstract][Full Text] [Related]
56. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
57. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?
Roeper J; Griesinger F
Curr Opin Oncol; 2019 Jan; 31(1):1-7. PubMed ID: 30451714
[TBL] [Abstract][Full Text] [Related]
58. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
59. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
Ménard L; Floc'h N; Martin MJ; Cross DAE
Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
[TBL] [Abstract][Full Text] [Related]
60. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]